Champions Oncology, Inc.
NASDAQ:CSBR · NASDAQ Capital Market
-$0.08 today
Vol 0.00M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
124.6%
avg -5009.6%
ROIC
48.6%
avg -339.1%
ROA
14.5%
avg -39.0%
Analysis
ROE is currently the strongest return metric at 124.6% versus its period average of -5009.6%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ronnie Morris | Executive Chair | $600,000.00 | — | 60 | $858,878.00 | 6.18% |
David Barry Miller | Chief Financial Officer | $308,333.00 | — | 57 | $21,216.00 | 0.15% |
Robert Brainin | Chief Executive Officer & Director | $20,000.00 | — | 55 | $361,663.00 | 2.60% |
Maria Mancini | Chief Operating Officer | — | — | — | — | — |
Marianna Zipeto | Executive Vice President of Growth, Strategy & Enablement | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A0 analysts |
| Revenue | N/A | N/A | +7.4% | +17.3% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +7.4% over three years. Forward estimates point to Revenue at +17.3% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$287.03M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$236.33M
Shattuck Labs, Inc.
NASDAQ:STTK
$231.97M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$155.72M
InflaRx N.V.
NASDAQ:IFRX
$130.74M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$126.24M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$89.68M
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
$88.71M
ImageneBio Inc
NASDAQ:IMA
$67.79M
Metagenomi, Inc. Common Stock
MGX
$45.74M
Who manages CSBR?
Champions Oncology, Inc. (CSBR) lists 5 active executives. The top listed executive is Maria Mancini, Chief Operating Officer.
Are CSBR insiders buying or selling?
Recent insider activity shows net buying of $5.77M.
Explore More
Continue the stock analysis
Jump to another research area for this company.